|
Variables
|
Whole-cohort AML
|
Non-M3 AML
|
CN-AML
|
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
Age
|
1.032 (1.016–1.047)
|
0.000
|
1.024 (1.008–1.041)
|
0.003
|
1.031 (1.012–1.051)
|
0.001
|
|
WBC
|
1.006 (1.001–1.010)
|
0.008
|
1.005 (1.000–1.009)
|
0.041
|
1.006 (1.001–1.011)
|
0.015
|
|
Molecular risks
|
2.112 (1.568–2.845)
|
0.000
|
2.101 (1.526–2.892)
|
0.000
|
1.769 (0.664–4.714)
|
0.254
|
|
Treatment regimen
|
0.421 (0.273–0.650)
|
0.000
|
0.389 (0.250–0.606)
|
0.000
|
0.614 (0.326–1.155)
|
0.131
|
|
SPAG1 expression
|
2.162 (1.465–3.191)
|
0.000
|
2.048 (1.377–3.047)
|
0.000
|
2.419 (1.354–4.320)
|
0.003
|
- AML: acute myeloid leukemia; CN-AML: cytogenetically normal AML; WBC: white blood cell. Variables including age (continuous variables), WBC (continuous variables), treatment regimen (with transplantation vs. without transplantation) and molecular risks (good, intermediate, poor, and unknown)
